Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CV 301

Next Previous
Drug Profile

CV 301

Alternative Names: CEA-MUC-1-TRICOM Vaccine; CEA-MUC-1/TRICOM; CV-301; CVAC-301; Falimarev-inalimarev; Inalimarev-falimarev; PANVAC; PANVAC V/F; PANVAC-VF

Latest Information Update: 02 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Therion Biologics
  • Developer BN ImmunoTherapeutics; Bristol-Myers Squibb; National Cancer Institute (USA); Therion Biologics
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Pancreatic cancer
  • Phase II Bladder cancer; Colorectal cancer; Non-small cell lung cancer; Prostate cancer
  • Discontinued Breast cancer; Ovarian cancer

Most Recent Events

  • 13 Sep 2024 Efficacy and adverse events data from a phase II trial in Prostate cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 01 Aug 2023 Georgetown University terminates a phase I/II trial in Pancreatic cancer and Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC), due to lack of enrollment (NCT03376659)
  • 10 Sep 2021 Efficacy data from a phase II trial in Bladder cancer presented at the 116th Annual Meeting of the American Urological Association (AUA-2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top